Source link : https://www.newshealth.biz/health-news/pulmonary-arterial-hypertension-drug-okd-by-europe/
At its June 2024 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave Winrevair (sotatercept; Merck Sharp & Dohme) a positive opinion for the treatment of patients with pulmonary arterial hypertension (PAH). Despite approved therapies for treating PAH, long-term prognosis remains poor. It is estimated that around 50% of patients […]
Author : News Health
Publish date : 2024-06-28 14:40:35
Copyright for syndicated content belongs to the linked Source.
Categories